vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.

Local Bounti Corporation is the larger business by last-quarter revenue ($12.5M vs $7.2M, roughly 1.7× Arcturus Therapeutics Holdings Inc.). On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs -68.4%). Local Bounti Corporation produced more free cash flow last quarter ($-3.6M vs $-74.5M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.

ARCT vs LOCL — Head-to-Head

Bigger by revenue
LOCL
LOCL
1.7× larger
LOCL
$12.5M
$7.2M
ARCT
Growing faster (revenue YoY)
LOCL
LOCL
+92.1% gap
LOCL
23.7%
-68.4%
ARCT
More free cash flow
LOCL
LOCL
$70.9M more FCF
LOCL
$-3.6M
$-74.5M
ARCT
Faster 2-yr revenue CAGR
LOCL
LOCL
Annualised
LOCL
21.9%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
LOCL
LOCL
Revenue
$7.2M
$12.5M
Net Profit
$-8.7M
Gross Margin
12.2%
Operating Margin
-106.1%
Net Margin
-69.8%
Revenue YoY
-68.4%
23.7%
Net Profit YoY
3.1%
76.0%
EPS (diluted)
$1.52

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
LOCL
LOCL
Q4 25
$7.2M
$12.5M
Q3 25
$17.2M
$12.2M
Q2 25
$28.3M
$12.1M
Q1 25
$29.4M
$11.6M
Q4 24
$22.8M
$10.1M
Q3 24
$41.7M
$10.2M
Q2 24
$49.9M
$9.4M
Q1 24
$38.0M
$8.4M
Net Profit
ARCT
ARCT
LOCL
LOCL
Q4 25
$-8.7M
Q3 25
$-13.4M
$-26.4M
Q2 25
$-9.2M
$-21.6M
Q1 25
$-14.1M
$-37.7M
Q4 24
$-30.0M
$-36.3M
Q3 24
$-6.9M
$-34.3M
Q2 24
$-17.2M
$-25.3M
Q1 24
$-26.8M
$-24.1M
Gross Margin
ARCT
ARCT
LOCL
LOCL
Q4 25
12.2%
Q3 25
11.5%
Q2 25
12.2%
Q1 25
12.6%
Q4 24
5.4%
Q3 24
13.8%
Q2 24
14.3%
Q1 24
9.4%
Operating Margin
ARCT
ARCT
LOCL
LOCL
Q4 25
-106.1%
Q3 25
-96.3%
-149.4%
Q2 25
-41.0%
-127.7%
Q1 25
-57.3%
-135.6%
Q4 24
-146.7%
-166.6%
Q3 24
-25.8%
-176.0%
Q2 24
-42.4%
-146.8%
Q1 24
-80.0%
-122.9%
Net Margin
ARCT
ARCT
LOCL
LOCL
Q4 25
-69.8%
Q3 25
-78.4%
-216.6%
Q2 25
-32.4%
-178.3%
Q1 25
-47.9%
-324.6%
Q4 24
-131.8%
-360.1%
Q3 24
-16.6%
-335.2%
Q2 24
-34.5%
-267.6%
Q1 24
-70.5%
-286.9%
EPS (diluted)
ARCT
ARCT
LOCL
LOCL
Q4 25
$1.52
Q3 25
$-0.49
$-1.18
Q2 25
$-0.34
$-1.63
Q1 25
$-0.52
$-4.32
Q4 24
$-1.10
$-4.24
Q3 24
$-0.26
$-4.01
Q2 24
$-0.64
$-3.00
Q1 24
$-1.00
$-2.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
LOCL
LOCL
Cash + ST InvestmentsLiquidity on hand
$230.9M
$4.2M
Total DebtLower is stronger
$483.1M
Stockholders' EquityBook value
$214.0M
$-166.2M
Total Assets
$271.1M
$410.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
LOCL
LOCL
Q4 25
$230.9M
$4.2M
Q3 25
$180.4M
$6.2M
Q2 25
$196.5M
$5.3M
Q1 25
$216.9M
$18.0M
Q4 24
$237.0M
$937.0K
Q3 24
$237.2M
$317.0K
Q2 24
$260.3M
$9.7M
Q1 24
$288.4M
$8.2M
Total Debt
ARCT
ARCT
LOCL
LOCL
Q4 25
$483.1M
Q3 25
$484.9M
Q2 25
$478.3M
Q1 25
$480.0M
Q4 24
$436.8M
Q3 24
$398.4M
Q2 24
$374.0M
Q1 24
$329.8M
Stockholders' Equity
ARCT
ARCT
LOCL
LOCL
Q4 25
$214.0M
$-166.2M
Q3 25
$224.6M
$-158.1M
Q2 25
$231.1M
$-132.7M
Q1 25
$233.8M
$-134.5M
Q4 24
$241.0M
$-100.5M
Q3 24
$261.9M
$-65.6M
Q2 24
$258.6M
$-32.8M
Q1 24
$264.0M
$-9.4M
Total Assets
ARCT
ARCT
LOCL
LOCL
Q4 25
$271.1M
$410.5M
Q3 25
$282.3M
$417.8M
Q2 25
$309.3M
$426.8M
Q1 25
$331.8M
$447.2M
Q4 24
$344.1M
$428.0M
Q3 24
$370.7M
$430.8M
Q2 24
$388.6M
$438.1M
Q1 24
$418.8M
$413.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
LOCL
LOCL
Operating Cash FlowLast quarter
$-74.3M
$-3.1M
Free Cash FlowOCF − Capex
$-74.5M
$-3.6M
FCF MarginFCF / Revenue
-1035.2%
-29.1%
Capex IntensityCapex / Revenue
3.2%
3.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-42.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
LOCL
LOCL
Q4 25
$-74.3M
$-3.1M
Q3 25
$-17.2M
$-8.9M
Q2 25
$-5.8M
$-8.7M
Q1 25
$-35.1M
$-9.6M
Q4 24
$-284.0K
$1.2M
Q3 24
$-23.8M
$-17.2M
Q2 24
$-30.1M
$-4.0M
Q1 24
$-5.6M
$-7.1M
Free Cash Flow
ARCT
ARCT
LOCL
LOCL
Q4 25
$-74.5M
$-3.6M
Q3 25
$-17.3M
$-10.1M
Q2 25
$-14.6M
Q1 25
$-35.3M
$-14.5M
Q4 24
$-8.6M
Q3 24
$-23.8M
$-30.0M
Q2 24
$-30.5M
$-28.8M
Q1 24
$-5.8M
$-42.1M
FCF Margin
ARCT
ARCT
LOCL
LOCL
Q4 25
-1035.2%
-29.1%
Q3 25
-101.1%
-82.8%
Q2 25
-121.0%
Q1 25
-120.1%
-125.1%
Q4 24
-85.3%
Q3 24
-57.2%
-293.1%
Q2 24
-61.1%
-305.4%
Q1 24
-15.3%
-501.8%
Capex Intensity
ARCT
ARCT
LOCL
LOCL
Q4 25
3.2%
3.9%
Q3 25
1.1%
9.7%
Q2 25
0.0%
48.9%
Q1 25
0.5%
42.8%
Q4 24
0.0%
97.6%
Q3 24
0.2%
125.0%
Q2 24
0.7%
263.0%
Q1 24
0.6%
417.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons